M

Moderna

D
MRNA
USD
-0.6
(-0.4777%)
Market Closed
220,716.00
Volume
-7.51
EPS
-
Div Yield
-10.137064
P/E
47,856,122,703.88
Market Cap
Today
-0.4777%
1 Week
15.742%
1 Month
23.471%
6 Months
61.236%
12 Months
-3.913%
Year To Date
25.631%
All Time
726.107%
Signals
avatar
Abdilatif
3 months ago
sell
M
MRNA@101.020
01.02.2024 09:45
Profit
357.00
TP1: 80.000
SL: 105.723
Close Price
97.450
Closed At
2024-02-05 09:51
avatar
Abdilatif
3 months ago
sell
M
MRNA@101.830
29.01.2024 10:09
Profit
-175.00
TP1: 101.829
TP2: 84.000
SL: 104.928
Close Price
105.330
Closed At
2024-01-29 18:15
More
News

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
PFE
PFE
0.12
(0.4331%)
USD
B
BNTX
0.51
(0.5531%)
USD
N
NVAX
0.19
(4.0254%)
USD
JNJ
JNJ
-0.68
(-0.4535%)
USD
G
GSK
0.15
(0.346%)
USD
AZN
AZN
0.57
(0.7519%)
USD
MRK
MRK
-0.77
(-0.6002%)
USD

Title:
Moderna

Sector:
Healthcare
Industry:
Biotechnology
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Do you need help or have a question?
Contact Us